Suppr超能文献

靶向细菌转录的肽的结构导向设计与评估

Structure-Guided Designing and Evaluation of Peptides Targeting Bacterial Transcription.

作者信息

Kaur Gundeep, Kapoor Srajan, Kaundal Soni, Dutta Dipak, Thakur Krishan Gopal

机构信息

Structural Biology Laboratory, G. N. Ramachandran Protein Centre, Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh, India.

Molecular Microbiology Laboratory, Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh, India.

出版信息

Front Bioeng Biotechnol. 2020 Sep 8;8:797. doi: 10.3389/fbioe.2020.00797. eCollection 2020.

Abstract

The mycobacterial RNA polymerase (RNAP) is an essential and validated drug target for developing antibacterial drugs. The β-subunit of RNAP (RpoB) interacts with an essential and global transcription factor, CarD, and confers antibiotic and oxidative stress resistance to . Compromising the RpoB/CarD interactions results in the killing of mycobacteria, hence disrupting the RpoB/CarD interaction has been proposed as a novel strategy for the development of anti-tubercular drugs. Here, we describe the first approach to rationally design and test the efficacy of the peptide-based inhibitors which specifically target the conserved PPI interface between the bacterial RNAP β/transcription factor complex. We performed protein-peptide docking studies along with biochemical assays to characterize the novel peptide-based inhibitors. Our results suggest that the top ranked peptides are highly stable, soluble in aqueous buffer, and capable of inhibiting transcription with IC > 50 μM concentration. Using peptide-based molecules, our study provides the first piece of evidence to target the conserved RNAP β/transcription factor interface for designing new inhibitors. Our results may hence form the basis to further improve the potential of these novel peptides in modulating bacterial gene expression, thus inhibiting bacterial growth and combating bacterial infections.

摘要

分枝杆菌RNA聚合酶(RNAP)是开发抗菌药物的一个重要且经过验证的药物靶点。RNAP的β亚基(RpoB)与一种重要的全局转录因子CarD相互作用,并赋予细菌抗生素抗性和氧化应激抗性。破坏RpoB/CarD的相互作用会导致分枝杆菌死亡,因此,破坏RpoB/CarD的相互作用已被提议作为开发抗结核药物的一种新策略。在此,我们描述了第一种合理设计并测试基于肽的抑制剂疗效的方法,这些抑制剂特异性靶向细菌RNAP β/转录因子复合物之间保守的蛋白质-蛋白质相互作用界面。我们进行了蛋白质-肽对接研究以及生化分析,以表征新型基于肽的抑制剂。我们的结果表明,排名靠前的肽高度稳定,可溶于水性缓冲液,并且能够在IC>50μM浓度下抑制转录。通过基于肽的分子,我们的研究提供了首个靶向保守的RNAP β/转录因子界面以设计新抑制剂的证据。因此,我们的结果可能为进一步提高这些新型肽调节细菌基因表达、从而抑制细菌生长和对抗细菌感染的潜力奠定基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/05fb/7505949/6c0113aad4a9/fbioe-08-00797-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验